Table 3.
Cognitive Composite Factor Scores Before and After 45 and 90 Days of Supplementation with Spearmint Extract
| Placebo | 600 mg Spearmint extract | 900 mg Spearmint extract | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 0 | Day 45 | Day 90 | Day 0 | Day 45 | Day 90 | Day 0 | Day 45 | Day 90 | |||
| Composite factors | Mean score (SEM) | p* | Directiona | ||||||||
| Power of attention (msec) | 1275.56 (26.46) |
1291.00 (25.90) |
1308.77 (28.48) |
1308.11 (22.23) |
1338.47 (24.73) |
1345.09 (25.22) |
1278.83 (16.87) |
1307.07 (17.85) |
1316.91 (21.11) |
0.9312 | ↑ |
| Continuity of attention (No.) | 66.11 (3.00) |
65.51 (3.13) |
67.80 (2.95) |
67.50 (2.17) |
67.86 (2.26) |
70.35 (1.60) |
66.86 (2.19) |
68.80 (1.68) |
68.38 (2.67) |
0.8881 | ↑ |
| Quality of working memory (No.) | 1.72 (0.04) |
1.79 (0.03) |
1.82 (0.03) |
1.77 (0.03) |
1.83 (0.03) |
1.84 (0.02) |
1.61 (0.06) |
1.80 (0.03) |
1.81b (0.02) |
0.0435 | ↑ |
| Quality of episodic secondary memory (No.) | 126.69 (5.88) |
143.06 (6.06) |
133.64 (9.16) |
133.33 (5.29) |
143.18 (5.98) |
139.91 (6.20) |
127.89 (7.28) |
137.83 (7.37) |
129.25 (7.80) |
0.8082 | ↑ |
| Speed of memory (msec) | 3829.22 (109.90) |
3681.86 (122.25) |
3564.54 (111.07) |
3824.15 (104.82) |
3679.49 (108.44) |
3559.19 (93.16) |
3939.63 (123.86) |
3740.41 (102.85) |
3653.68 (99.13) |
0.6460 | ↑ |
| Quality of memory (No.) | 298.38 (8.30) |
321.51 (8.51) |
315.54 (11.15) |
310.20 (6.71) |
325.22 (7.28) |
323.66 (7.29) |
288.19 (10.33) |
316.93 (8.73) |
309.93 (9.01) |
0.2296 | ↑ |
Bold values indicate overall treatment effects, p < 0.05.
The computerized cognitive performance battery (CDR System™; Bracket, LLC) was administered at baseline (day 0) and after 45 and 90 days of spearmint extract or placebo supplementation.
The arrow notes the direction of change that suggests improvement in the associated outcome.
900 mg/day spearmint extract versus placebo, p = 0.0469; 900 mg/day spearmint extract versus 600 mg/day spearmint extract, p = 0.0212.
p-Values for the overall and pairwise comparisons in the intent-to-treat sample were generated from a mixed-model repeated-measures analysis of variance model based on the average daily difference from baseline (n = 28–30/group).
CDR, Cognitive Drug Research; SEM, standard error of the mean.